• VE-821 ATR Kinase Inhibitor: Pushing DNA Damage Research Bou

  2026-06-25

  Explore how VE-821, a potent ATR kinase inhibitor, is revolutionizing DNA damage response and radiosensitization research. This article uniquely bridges mechanistic insights and experimental best practices, setting a new benchmark for DNA repair pathway studies.

• Clathrin-Mediated Endocytosis Enables Grass Carp Reovirus En

  2026-06-25

  This study by Wang et al. demonstrates that genotype III grass carp reovirus (GCRV104) utilizes clathrin-mediated, dynamin-dependent endocytosis for cellular entry in kidney cell models. The findings clarify a key aspect of GCRV104 infection pathways, with practical implications for antiviral strategy development and mechanistic research.

• Sunitinib (SKU B1045): Reliable RTK Inhibitor for Oncology R

  2026-06-24

  This article addresses critical laboratory challenges in cell viability and proliferation assays, demonstrating how Sunitinib (SKU B1045) from APExBIO offers reproducible, data-backed solutions for studies in renal cell carcinoma and beyond. Practical protocol guidance, evidence-based troubleshooting, and vendor selection insights help researchers optimize workflows and interpret results with confidence.

• Recombinant Mouse Sonic Hedgehog: Optimizing Developmental A

  2026-06-23

  Recombinant Mouse SHH from APExBIO powers precision patterning studies and congenital malformation research with validated performance in key morphogenetic workflows. Learn how reference-driven protocols and targeted troubleshooting maximize assay outcomes for limb, brain, and urogenital development models.

• Munc18c–Syntaxin4 Interaction Drives Tumor Cell Invasion via

  2026-06-23

  This study reveals how the interaction between Munc18c and syntaxin4 (Stx4) orchestrates the formation of invadopodia, specialized structures that enable tumor cells to invade the extracellular matrix. By dissecting SNARE-mediated trafficking pathways, the authors clarify the molecular regulation of matrix metalloproteinase and EGF receptor localization during cancer cell invasion, providing a foundation for future mechanistic and therapeutic research.

• BODIPY 581/591 C11: Ratiometric Probing of Lipid Peroxidatio

  2026-06-22

  Explore how BODIPY 581/591 C11 enables ratiometric fluorescent detection of lipid peroxidation in cardiovascular oxidative stress models. This article provides a mechanistic deep dive, advanced comparative insights, and protocol guidance beyond existing resources.

• 1-methyl Adenosine: Modernizing RNA Modification and Biomark

  2026-06-22

  This thought-leadership article explores the multifaceted role of 1-methyl Adenosine in RNA modification research, biomarker discovery, and translational oncology. It provides mechanistic insight, strategic assay recommendations, and a vision for emerging clinical applications, blending state-of-the-art analytical advances with actionable guidance for researchers.

• TAK1-YAP Axis Drives Self-Renewal in Gastric Cancer Stem Cel

  2026-06-21

  This study uncovers how TGFβ-activated kinase 1 (TAK1) stabilizes yes-associated protein (YAP), promoting self-renewal and oncogenesis in gastric cancer stem cells (GCSCs). By elucidating the TAK1-YAP-SOX2/SOX9 signaling axis, the findings highlight new molecular targets for addressing chemoresistance and recurrence in gastric cancer.

• TBK1 Inhibition Mitigates Diabetic Neuropathy via Microglial

  2026-06-20

  Liao et al. (2024) uncover a pivotal role for TANK-binding kinase 1 (TBK1) in the development of painful diabetic neuropathy (PDN) through microglial pyroptosis. Their findings establish TBK1 as a potential therapeutic target, showing that both genetic and pharmacological inhibition of TBK1 can alleviate neuropathic pain and nerve injury in diabetic mouse models.

• GZMK+ CD8+ T Cells Drive Recurrence in Airway Inflammatory D

  2026-06-19

  A recent study identified persistent GZMK-expressing CD8+ T cell clones as key drivers of recurrent nasal polyps and airway inflammation. The work reveals how these memory-like cells activate the complement cascade and contribute to disease chronicity, highlighting a new therapeutic target.

• ERK Inhibition Mitigates Mitochondrial Fragmentation in OGD/

  2026-06-19

  Yuan et al. (2023) reveal that suppressing ERK signaling protects neuroblastoma SH-SY5Y cells from oxygen-glucose deprivation/reoxygenation (OGD/R) injury by reducing mitochondrial fragmentation and autophagy. This work clarifies the ERK–Drp1/Mfn2–autophagy axis in cerebral ischemia-reperfusion injury, highlighting new avenues for targeting neuronal survival.

• Iron-Dependent KDM4D Regulates MSC Fate via PI3K-Akt-Foxo1 P

  2026-06-18

  This study reveals how iron deficiency represses mesenchymal stem cell (MSC) activation by reducing KDM4D demethylase activity, leading to altered PI3K-Akt-Foxo1 signaling. The findings establish a mechanistic link between iron metabolism, epigenetic regulation, and bone remodeling, providing new targets for osteoporosis and metabolic disease research.

• Pazopanib (GW-786034): Rethinking RTK Inhibition in Translat

  2026-06-18

  This thought-leadership article explores how Pazopanib (GW-786034), a potent multi-targeted receptor tyrosine kinase inhibitor, is reshaping strategies in translational cancer research. Leveraging mechanistic insights and recent evidence—particularly in ATRX-deficient high-grade gliomas—the piece guides researchers through experimental design, validation, and strategic considerations for maximizing impact and reproducibility, while positioning APExBIO's offering as a cornerstone for innovative workflows.

• SGC-CBP30: Precision CREBBP/EP300 Bromodomain Inhibitor Work

  2026-06-17

  SGC-CBP30 enables selective, nanomolar-range inhibition of CREBBP/EP300 bromodomains, empowering advanced epigenetics and cancer biology research. Leverage its potency for dissecting super-enhancer-driven transcriptional circuits and streamlining workflows in lung adenocarcinoma and beyond.

• Leveraging 3-Deazaadenosine HCl to Decode HSC Activation in

  2026-06-17

  This thought-leadership article explores the mechanistic and strategic impact of 3-Deazaadenosine hydrochloride as a selective S-adenosylhomocysteine hydrolase (SAHH) inhibitor in translational liver fibrosis research. Integrating mechanistic evidence on hepatic stellate cell (HSC) activation via the IGF2BP1–m6A–TUBB4B axis, the article offers guidance on experimental design, competitive positioning, and translational potential, highlighting how APExBIO's high-purity compound advances fibrosis models beyond generic product discussions.

445 records 13/30 page Previous Next First page 上5页 1112131415 下5页 Last page